Standout Papers

BCLC strategy for prognosis predictio... 2013 2026 2017 2021 2.2k
  1. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update (2021)
    María Reig, Alejandro Forner et al. Journal of Hepatology
  2. Hepatocellular carcinoma (2016)
    Josep M. Llovet, Jessica Zucman‐Rossi et al. Nature Reviews Disease Primers
  3. Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade (2014)
    Philip J. Johnson, Sarah Berhane et al. Journal of Clinical Oncology
  4. Advances in immunotherapy for hepatocellular carcinoma (2021)
    Bruno Sangro, Pablo Sarobe et al. Nature Reviews Gastroenterology & Hepatology
  5. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C (2013)
    Bruno Sangro, Carlos Gómez-Martín et al. Journal of Hepatology
  6. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy (2016)
    María Reig, Zoe Mariñó et al. Journal of Hepatology
  7. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2018)
    Arndt Vogel, Andrés Cervantes et al. Annals of Oncology
  8. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) (2019)
    Thomas Yau, Richard S. Finn et al. Annals of Oncology
  9. Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions (2013)
    Andrew K. Burroughs, Jean‐François Dufour et al. Seminars in Liver Disease
  10. Immunological landscape and immunotherapy of hepatocellular carcinoma (2015)
    Jesús Prìeto, Ignacio Melero et al. Nature Reviews Gastroenterology & Hepatology
  11. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization (2010)
    Jean‐Luc Raoul, Bruno Sangro et al. Cancer Treatment Reviews
  12. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines (2021)
    Arndt Vogel, Erika Martinelli et al. Annals of Oncology
  13. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma (2020)
    Bruno Sangro, Ignacio Melero et al. Journal of Hepatology
  14. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. (2022)
    Ghassan K. Abou‐Alfa, Stephen L. Chan et al. Journal of Clinical Oncology
  15. Systemic treatment of hepatocellular carcinoma: An EASL position paper (2021)
    Jordi Bruix, Stephen L. Chan et al. Journal of Hepatology
  16. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma (2019)
    Jens Ricke, Heinz‐Josef Klümpen et al. Journal of Hepatology
  17. Combination immunotherapy for hepatocellular carcinoma (2023)
    Lorenza Rimassa, Richard S. Finn et al. Journal of Hepatology
  18. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis (2021)
    Masatoshi Kudo, Ana Matilla et al. Journal of Hepatology
  19. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma (2023)
    Domenico Alvaro, Gregory J. Gores et al. Journal of Hepatology
  20. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. (2024)
    Riccardo Lencioni, Masatoshi Kudo et al. Journal of Clinical Oncology
  21. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma (2024)
    Bruno Sangro, Lorenza Rimassa et al. Journal of Hepatology
  22. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. (2024)
    Peter R. Galle, Thomas Decaens et al. Journal of Clinical Oncology

Immediate Impact

7 by Nobel laureates 6 from Science/Nature 92 standout
Sub-graph 1 of 16

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
2024 Standout
124 intermediate papers

Works of Bruno Sangro being referenced

Abstract 2145: Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial
2022
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
and 74 more

Author Peers

Author Last Decade Papers Cites
Bruno Sangro 15541 7306 8005 410 24.8k
Lewis R. Roberts 12828 6113 9380 417 28.4k
Riccardo Lencioni 19952 4668 10252 280 27.9k
Jean‐Luc Raoul 11273 11767 9141 341 25.6k
Philip J. Johnson 11341 5686 8348 311 21.0k
Valérie Paradis 11714 4448 12909 430 24.2k
Michiie Sakamoto 7826 5428 5523 402 20.0k
Andrew X. Zhu 16657 12437 8134 415 33.7k
Vincenzo Mazzaferro 24135 7444 14779 357 36.6k
Myron Schwartz 12616 3824 6754 325 20.3k
Peter Schirmacher 10370 11352 8936 673 35.7k

All Works

Loading papers...

Rankless by CCL
2026